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Abstract
Background: Transurethral resection of the prostate (TURP) and Greenlight laser vaporisation (GL) of the prostate
are frequently performed urological procedures. For TURP, a single-dose antimicrobial prophylaxis (AP) is recommended
to reduce postoperative urinary tract infections. So far, no international recommendations for AP have been established
for GL. In a survey-based study in Switzerland, Germany and Austria, urologists reported routinely extending AP primarily
for 3 days after both interventions. We therefore aim to determine whether single-dose AP with cotrimoxazole is
non-inferior to 3-day AP with cotrimoxazole in patients undergoing TURP or GL of the prostate.
Methods/design: We will conduct an investigator-initiated, multicentre, randomised controlled trial. We plan to
assess the non-inferiority of single-dose AP compared to 3-day AP. The primary outcome is the occurrence of
clinically diagnosed symptomatic urinary tract infections which are treated with antimicrobial agents within 30
days after randomisation. The vast majority of collected outcomes will be assessed from routinely collected data.
The sample size was estimated to be able to show the non-inferiority of single-dose AP compared to 3-day AP
with at least 80% power (1 – β = 0.8) at a significance level of α = 5%, applying a 1:1 randomisation scheme. The
non-inferiority margin was determined in order to preserve 70% of the effect of usual care on the primary outcome.
For an assumed event rate of 9% in both treatment arms, this resulted in a non-inferiority margin of 4.4% (i.e. 13.4% to
9%). To prove non-inferiority, a total of 1574 patients should be recruited, in order to have 1416 evaluable patients. The
study is supported by the Swiss National Science Foundation.
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Discussion: For AP in TURP and GL, there is a large gap between usual clinical practice and evidence-based guidelines.
If single-dose AP proves non-inferior to prolonged AP, our study findings may help to reduce the duration of AP in daily
routine—potentially reducing the risk of emerging resistance and complications related to AP.
Trial registration: Clinicaltrials.gov, NCT03633643. Registered 16 August 2018.
Keywords: Transurethral resection of prostate, Greenlight laser vaporisation, Antibiotic prophylaxis, Urinary tract infection,
Randomised controlled trial
Background
Transurethral resection of the prostate (TURP) is one of
the most frequently performed urological procedures and is
associated with inpatient antibiotic use [1]. Photoselective
vaporisation with the Greenlight laser (GL) has become an
important therapeutic alternative to TURP, in particular for
patients under anticoagulation [2]. According to the World
Health Organization (WHO), TURP belongs to the ca-
tegory of “clean-contaminated” operative procedures [3].
Therefore, routine antimicrobial prophylaxis (AP)—ideally
a single dose of the trimethoprim/sulfamethoxazole com-
bination (TMP/SMX; cotrimoxazole is the combination
product) with or without amino-penicillin/beta-lactamase
inhibitor or cephalosporins—is recommended by the Euro-
pean Association of Urology (EAU) guidelines [4].
The bases of these guidelines are several meta-ana-
lyses [5–7] assessing the effects of various AP schemes
compared to placebo. A systematic review and
meta-analysis published in 2013 including a total of 42
clinical trials (randomised and quasi-randomised; 7496
patients) indicated that, in urological surgery, AP ver-
sus placebo substantially reduced the risk for bacte-
riuria (risk ratio (RR) 0.36, 95% confidence interval (CI)
0.29 to 0.46), urinary tract infections (UTIs) (RR 0.38,
95% CI 0.28 to 0.51), bacteraemia (RR 0.43, 95% CI
0.23 to 0.82) and fever above 38.5 °C (RR 0.41, 95% CI
0.23 to 0.73). This and the other afore-mentioned
meta-analyses indicate that AP is superior compared to
no AP for patient-relevant clinical outcomes (e.g. UTI,
fever, sepsis) as well as for laboratory outcomes (e.g.
bacteriuria, bacteraemia) [5–7].
Henceforth, to reduce postoperative UTIs after TURP,
single-dose AP is recommended by the EAU guidelines
[4]. A similar non-invasive intervention for prostatic
hyperplasia is GL. There are, to our knowledge, no inter-
national guideline recommendations for AP though the
surgical techniques and the knowledge about antimicro-
bial resistance have evolved, there still is overuse of anti-
microbial agents for AP in TURP and GL of the prostate.
In a preliminary study, we observed a non-adherence in
TURP and GL to the recommended single-dose AP of
more than 70% amongst urologists in Switzerland,
Germany and Austria. AP in TURP and GL was regularly
extended up to several days; the most common duration
of AP was 2–3 days [8].
Clinical evidence to date
In a systematic literature search in PubMed (last search
20 March 2018; detailed search strategy listed in Add-
itional file 1, page 58), we identified five RCTs which
assessed the efficacy of single-dose AP compared to
prolonged AP (2–4 days or until catheter removal) of
the same therapeutic compound. The largest study was
conducted by Hargreave et al. [9] between 1987 and
1989 in nine European centres. Patients were rando-
mised to receive single-dose ceftazidime (n = 257),
continuing daily ceftazidime until catheter removal
(n = 264) or no AP at all (n = 274). The study was
designed so that a difference of 9% in UTIs could be
detected between the non-AP group and the two AP
groups. UTIs were observed significant more fre-
quently in patients who received no AP (33.9%; 83 of
245) compared to single-dose AP (18.7%; 45 of 240)
or continuous AP (11.6%; 29 of 250). Furthermore,
single-dose AP resulted in significantly more UTIs
compared to continuous AP. Another study, which
was published in 1984, randomised patients to receive
either a single dose of cefotaxime (1 g) or several
doses over a 48-h regime (cefotaxime 500 mg every
12 h) [10]. From the 106 patients who received a sin-
gle dose, 47 had at least one complication; while in
the 48-h regime, only 24 of 97 patients had any com-
plications. It remained unclear how complications
were assessed. In an RCT published in Japanese, Tsu-
gawa et al. [11] randomised patients to either a single
dose of cefazoline (n = 92) or a 3-day course of cefa-
zoline (n = 96). No difference in fever incidence
(1-day AP, 3.3%; 3-day AP, 4.2%) or mean days until
normalisation of urine analysis (1-day AP, 68.4 days;
3-day AP, 68.6 days) was observed. Two RCTs con-
ducted by Hall et al. [12] and Costa [13] had rela-
tively small sample sizes. Hall et al. randomised
patients to either an oral dose of fleroxacin (n = 28),
a single intravenous (IV) dose of fleroxacin (n = 29)
or an initial IV dose of fleroxacin followed by daily
oral fleroxacin until catheter removal but maximally
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until 5 days. No difference in the rate of UTIs (in-
cluding urosepsis and fever) was observed among
treatment arms (7.1% (2/28), 6.8% (2/29) and 7.4% (2/
27)) in the first 6 weeks after surgery [12]. In the
other RCT, men received a single perioperative dose
of lomefloxacin (n = 20) or perioperative lomefloxacin
plus daily lomefloxacin thereafter for 3 days (n = 20)
[13]. A total of two patients and one patient devel-
oped bacteriuria in the single AP group and in the
3-day AP group, respectively. Adverse events (AEs)
(e.g. nausea, vomiting and headache) seemed to be
more common in the 3-day AP group.
In summary, the identified RCTs were all relatively old
(published between 1984 and 1998) and none assessed the
currently recommended drug combination TMP/SMX
(i.e. cotrimoxazole). Furthermore, the heterogeneity
among the studies was high and several studies did not as-
sess patient-relevant outcomes.
A search on the International Clinical Trials Registry
Platform (ICTRP) from the WHO (last search 20 March
2018) was conducted to assess whether there are currently
ongoing RCTs which assess the impact of single-dose AP
compared to prolonged AP for TURP and GL. One RCT
was identified (CTRI/2017/09/009721) which plans to
evaluate the efficacy of 1 day of amikacin compared to 3
days in patients undergoing TURP. For this identified trial,
the target sample size is 334 patients and the primary out-
come is the rate of bacteriuria 4 days after TURP.
In this multicentre RCT, we investigate the non-infer-
iority of single-dose AP with cotrimoxazole against
3-day AP with cotrimoxazole in terms of a patient-rele-
vant outcome (i.e. the proportion of UTIs within 30
days, which require antimicrobial treatment) in patients




This is a randomised controlled, non-inferiority, parallel
group, double-blinded trial with a 1:1 randomisation ratio
in five urological departments in Switzerland (i.e. Univer-
sity Hospital Basel, St. Claraspital Basel, University Hos-
pital Zurich, Cantonal Hospital Aarau, Cantonal Hospital
Baselland). Study participants will either be randomly allo-
cated to guideline-conforming single-dose AP (Group A)
or to 3-day AP which is currently considered usual clinical
care in Switzerland (Group B). The trial will be based on
routinely collected data during TURP and GL of the pros-
tate until day 30 after surgery (Fig. 1).
Patients
Patients scheduled for TURP or GL due to voiding disor-
ders (e.g. benign prostate hyperplasia, obstructive prostate
cancer) at the five study sites in Switzerland who meet the
eligibility criteria (Table 1) will be asked to participate. In-
formed consent will take place at the outpatient clinic,
when the surgery is planned.
Outcomes
All outcomes are events within 30 days (±5 days) after
randomisation if not otherwise stated.
Primary outcome
Symptomatic UTI (based on clinical diagnosis) treated
with antibiotics (as per clinical judgement of the treating
physician).
Secondary outcomes
a) Symptomatic UTI (based on clinical diagnosis
and judgement of the treating physician
supported by measured bacteriuria of ≥105
colony forming units (cfu)/ml) treated with
antibiotics (key secondary outcome).
b) Symptomatic cystitis (based on clinical diagnosis).
c) Symptomatic epididymitis (based on clinical
diagnosis).
d) Symptomatic pyelonephritis (based on clinical
diagnosis).
e) Symptomatic prostatitis (based on clinical diagnosis).
f ) Symptomatic urethritis (based on clinical diagnosis).
g) Urosepsis (based on clinical diagnosis).
h) Prescription of antibiotics (for any reason).
i) Asymptomatic bacteriuria of ≥105 cfu/ml treated
with antibiotics.
j) Detection of multidrug-resistant bacteria in urine
culture (three multi-resistant Gram-negatives
(MRGN), 4MRGN).
k) Any Clostridium difficile-associated infection.
l) Re-hospitalisation (within 30 days after
randomisation).
m) All-cause mortality.
n) Duration of catheterisation (cumulative sum of days
between randomisation and end of catheterisation
or day 30).
o) Duration of hospital stay (cumulative sum of
hospital days between randomisation and day 30).
p) Duration of intensive care unit stay (cumulative sum
of ICU days between randomisation and day 30).
q) Prescribed defined daily doses (DDD) of
antibiotics (cumulative sum of DDD from
randomisation to day 30).
r) Change of International Prostate Symptom Score
(prior to surgery and at day 30 after
randomisation) [14].
s) Change of Quality of life Score (prior to surgery
and at day 30 after randomisation) [14].
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Safety outcomes
– Adverse events (AEs), including adverse events of
special interests (i.e. diarrhoea, nausea, vomiting,
allergic reaction and neurological disorder).
– Serious adverse events (SAEs), defined as any
untoward medical occurrence that results in death,
is life-threatening, results in re-hospitalisation or re-
sults in persistent or significant disability/incapacity.
Randomisation
Patients will be randomly allocated to one of the treat-
ment arms in a 1:1 ratio. Randomisation will be per-
formed via the electronic data capture (EDC) system,
which is accessible via a standard Internet browser. The
investigators will enter patient details into the electronic
case report form (eCRF) via a secure web interface be-
fore randomisation takes place. The randomisation pro-
cedure will include a variance minimisation algorithm
Fig. 1 Flowchart of study design. GL Greenlight laser vaporisation, iv intravenous, TMP/SMX trimethoprim/sulfamethoxazole (cotrimoxazole), TURP
transurethral resection of the prostate
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which will ensure that the treatment arms are balanced
for some potential confounder variables, specifically
centre and surgery type (TURP or GL). In order to avoid
predictable alteration of treatment allocation, and thus
potential loss of allocation concealment, patients will be
allocated with a probability of 0.80 to each treatment
group that would minimise the difference between the
groups on the key prognostic factor.
Intervention
On the day of surgery, the anaesthetists (not related to
the study) and the study nurse will be informed via the
hospital information system that the patient is included
in the study and that TMP/SMX (two ampoules of
TMP/SMX 400/80 mg solved in 250ml sodium chloride
short infusion) has to be used as AP.
After surgery, the nurses will be informed via the hospital
information system that the patient needs to receive the
oral study medication. Patients randomised to Group A will
receive an oral placebo on the evening of the surgery and
thereafter twice daily on days 1 and 2 after randomisation
(after breakfast and dinner). Patients randomised to Group
B will receive oral TMP/SMX (Nopil forte®) 800/160mg on
the evening of the surgery and thereafter twice daily on day
1 and 2 after randomisation (after breakfast and dinner).
Blinding
Physicians, patients and outcome assessors will be
blinded. The manufacturing and blinding of the study
medication will be performed by the Hospital Pharmacy
of the University Hospital Basel according to Good
Manufacturing Practice. Each study medication package
consists of either five tablets of placebo (Group A) or
five tablets of TMP/SMX (Nopil forte®) 800/160 mg
using a licensed product repacked in a new primary
packaging which is blinded.
The 500mg placebo tablets, purchased from Fagron
GmbH & Co., are optically similar but not identical to
TMP/SMX (Nopil forte®) 800/160mg. Perfectly identical
placebos were not available. The blinding is ensured via
non-transparent primary packaging. After randomisation,
the study team will provide the corresponding medication
number to a nurse who is responsible for drug distribu-
tion. This nurse will bring the study medication to the
patient and instruct the patient when to take the tablets.
Patients will then take the study drug by themselves.
The nurse will regularly ask whether the study drug was
taken and will document this information in the hospital
information system. If an unblinding due to safety con-
cerns is required, local investigators and the delegated
study personnel can decide on unblinding. Otherwise,
the EDC software secuTrial® allows for unblinding by
selected users (as defined in the data management plan).
Each unblinding will automatically be documented in
secuTrial®. Unblinding by opening the re-sealed study
medication is prohibited but the possibility to do so can-
not be ruled out.
Study visits
An overview of all study visits and the conducted study
procedures and assessments is presented in Fig. 2. Du-
ring the entire duration of the study, all SAEs are col-
lected, fully investigated and documented in source
documents and eCRFs.
Enrolment
For each patient at enrolment (approximately 7 days
before surgery), the eligibility screen, informed consent
and assessment of baseline variables (study site, study
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
• Adult male patients (≥18 years)
• Obstructive voiding disorder
(e.g. benign prostate hyperplasia, obstructive prostate cancer)
• Planned TURP or GL
• Evidence for (catheter-associated) UTI, with
or without antibiotic treatment in the last
7 days prior to randomisation
• Any evidence of a history of positive urine
culture (cfu ≥ 105/ml in midstream urine with
no more than two species) and resistance to
TMP/SMX in the last 7 days prior to randomisation [24]
• Known contraindication against study drugs
according to the Swissmedic package leaflet
(e.g. patients with known liver dysfunction, renal
insufficiency or glomerular filtration rate
(calculated by the MDRD or CKD-EPI) < 30 ml/min
or dialysis patients will be excluded)
• Antibiotic treatment for any reason within
7 days prior to randomisation
• Indication for AP for other reasons
(e.g. endocarditis prophylaxis, transplanted patients
under systemic immunosuppression)
AP antimicrobial prophylaxis, cfu colony forming units, CKD-EPI Chronic Kidney Disease Epidemiology Collaboration, GL Greenlight laser vaporisation, MDRD
Modification of Diet in Renal Disease, TMP/SMX trimethoprim/sulfamethoxazole (cotrimoxazole), TURP Transurethral resection of the prostate, UTI urinary
tract infection
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Fig. 2 Study procedures and assessments. AP antimicrobial prophylaxis, ASA American Society of Anaesthesiologists, BMI body mass index, cfu
colony forming units, DDD defined daily doses, ID identification (number), ICU intensive care unit, MRGN multi-resistant Gram-negatives, PSA
prostate specific antigen, UTI urinary tract infection. *Between hospital discharge and close-out visit
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ID, BMI, ASA score, blood counts, anticoagulation, PSA,
prostate volume, post-voiding residual volume, cathe-
terisation, International Prostate Symptom Score/Quality
of Life score, history of UTIs) are performed by the
physician who is also doing the informed consent talk
for the planned surgery.
Allocation
Before the randomisation takes place, each patient will
undergo a final eligibility check based on all available evi-
dence from the laboratory at that time point and based on
asking the patient (i.e. evidence for UTI, cfu ≥ 105/ml or
antibiotic treatment in the last 7 days before surgery). If all
questions can be answered with no (i.e. no evidence for
UTI, for cfu ≥105/ml or for antibiotic treatment in the last
7 days before surgery), the patient will be randomised and
will receive an identification code number via eCRF. The
assessed parameters from the surgery are listed in Fig. 2. In
the evening after the operation, the patients will receive a
drug container with the study medication (i.e. five tablets).
They will be instructed to swallow one tablet on the eve-
ning of day 0 and the consecutive four tablets on day 1
and day 2 (always one after breakfast and one after dinner).
Days 1 and 2
Nurses will remind the patients about the intake of
each tablet.
Day 3
At day 3, a urine culture (with antimicrobial resistance
pattern) is performed. Furthermore, AEs of special interest
as well as other potential AEs will be assessed. The study
nurse will acoustically check whether the container with
the study medication is empty. Drug containers which are
not empty will be sent back to the Hospital Pharmacy of
the University Hospital Basel where the remaining tablets
will be counted and destroyed by an unblinded employee,
who is not further involved in the study. The eCRF con-
tains a form to enter the number of remaining tablets,
which is only accessible for users of the Hospital Phar-
macy of the University Hospital Basel.
Unscheduled visits
Any unscheduled visits occurring during hospital dis-
charge will be assessed at the 30-day follow-up by con-
sulting the hospital information system and by asking
the patient.
Follow-up after 30 days
All endpoints will be assessed at day 30 (±5 days; for
more details, see “Assessment of outcomes”). In the case
that a patient does not attend the 30-day visit, the treat-
ing physician or the study nurse will try to find an alter-
native date within the 5-day window. If this is not
possible, the requested information for the primary end-
point will be asked by telephone.
Assessment of outcomes
The vast majority of outcomes will be assessed within the
routine follow-up at 30 days using routinely collected data
from the hospital information system. Additionally, patients
will be asked at the 30-day follow-up visit whether any
symptoms occurred since the hospital discharge, whether
symptoms were potentially related to a UTI (i.e. flank pain,
suprapubic pain, urgency, frequency, fever), whether a
physician was consulted and whether antibiotics were
taken. If any of these questions are answered with yes (or if
the answer remains unclear/doubtful), the information will
be confirmed by contacting the treating physician.
We generally assume that the hospital information sys-
tem at each study site provides highly accurate informa-
tion. However, we will evaluate the agreement of data
captured via the hospital information system and actively
collected data (e.g. by confirmation from the treating
physician) to understand the accuracy and reliability of
these data. In case there is any disagreement between the
data sources, the physician who conducted the 30-day
follow-up (or in case of no appearance, who was supposed
to conduct the 30-day follow-up) will document and re-
solve these discrepancies.
Assessment of primary outcome
The primary outcome will be assessed at the routine con-
trol 30 days after randomisation. The following procedure
will be followed:
(1) Before the patient arrives, the clinician who will
perform the routine control or the study nurse will
consult the hospital information system and assess
whether the primary endpoint occurred during the
hospital stay or whether the patient was re-
hospitalised due to a symptomatic UTI (based on
clinical diagnosis) treated with antibiotics.
(2) During the routine control, the clinician will check
whether the primary endpoint is currently present
and, additionally, the patient will be asked whether
they received any antibiotics or had a diagnosis of a
UTI between hospital discharge and the routine
control.
(3) In the case that the patient reports that either an
antibiotic was taken or such a diagnosis was made
(and also if any uncertainty about the non-occurrence
of the primary endpoint exists), the following clinician
will be contacted:
a) the treating physician (typically the patient’s
general practitioner), or
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b) the corresponding physician who prescribed the
antibiotics or made the diagnosis to confirm the
primary endpoint.
In case the patient misses the follow-up routine con-
trol at 30 days, the routine control will be re-scheduled
(the date must not be longer than 35 days after rando-
misation). If this is not possible, information following
the same procedure as earlier (points (1)–(3)) is followed
but the patient is called via telephone and asked about
the occurrence of the primary endpoint.
Assessment of secondary outcomes
The detailed assessment of the secondary outcomes is
described in the full study protocol, which was approved
by the research ethical committee (see Additional file 1).
Assessment of safety outcomes
To assess any potential harms, the study team evaluates
SAE according to the ICH E2A guidelines [15] as “defi-
nitely”, “probably”, “possibly”, “unlikely” and “not related”.
The “Common Terminology Criteria for Adverse Events”,
Version 5.0 terminology is going to be used for (S)AEs oc-
curring throughout this study: 1 = mild (does not influ-
ence activities of daily living), 2 = moderate (influences
activities of daily living), 3 = severe (makes some activities
of daily living impossible), 4 = life-threatening, 5 = death.
Assessments in participants who prematurely stop the study
Enrolled patients always have the opportunity to with-
draw from the trial at any time without mentioning any
specific reason. In the case of a severe adverse reaction,
the study drug will be stopped immediately and neces-
sary treatment will be performed. In the case of any
complication that requires antimicrobial therapy, the
study drug will be stopped. Participations who stop the
study drug or withdraw consent will be asked whether
they are anyway willing to conduct the routine follow-up
visit 30 days after surgery.
Concomitant care
Concomitant interventions are allowed whenever neces-
sary as part of the usual care which is based on the clinical
judgement of the physician. Concomitant medications of
special interest that patients take regularly at baseline are
non-steroidal anti-inflammatory drugs (NSAIDs), anticoa-
gulation, antiplatelet drugs and immunosuppressive drugs
(e.g. steroids). Concomitant medications of special interest
within the first 3 days after randomisation are NSAIDs.
Sample size calculation
The primary objective is to evaluate whether single-dose
AP with TMP/SMX is non-inferior to 3-day AP with
TMP/SMX (i.e. usual clinical care) regarding event rates
of symptomatic UTIs. The non-inferiority margin is de-
fined as the absolute difference in the event rates. The
sample size was estimated to be able to show the
non-inferiority of single-dose AP compared to 3-day AP
with at least 80% power (1 – β = 0.8) at a significance
level of α = 5%, applying a 1:1 randomisation scheme. A
drop-out rate of 10% was considered.
For determination of the non-inferiority margin δ, there
are no direct data available describing the effect of 3-day
AP with TMP/SMX versus placebo on our primary end-
point. Based on internal data from the involved clinics (see
Additional file 1, page 48), we assumed an expected UTI
rate within 30 days under usual care (3-day AP) of 0.09
(9%). A comprehensive meta-analysis [5] reported an over-
all risk ratio (RR) for symptomatic UTIs treated with AP
versus placebo of 0.38. Applied to an expected UTI rate
under 3-day AP of 9%, this corresponds to an expected
(hypothetical) UTI rate under placebo of 23.68% (i.e.
0.2368 × 0.38 = 0.09) and an expected absolute treatment
effect (absolute risk reduction (ARR)) of 3-day AP versus
placebo (M1) of 14.68% (ARR = 0.2368 – 0.09 = 0.1468).
The non-inferiority margin was determined in order to
preserve 70% of M1 (i.e. ARR × 0.7; 10.28% on an absolute
scale), which was judged a clinically important fraction.
This would correspond to an absolute event rate under
1-day AP versus placebo of 13.4% (i.e. 0.2368 –0.1028
= 0.134). Assuming an event rate of 0.09 (9%) in both
treatment arms, this resulted in a non-inferiority margin
of 4.4% (i.e. 13.4% to 9%). For an assumed event rate of
9% in both treatment arms, and a non-inferiority margin
of 4.4%, a total of 1574 patients should be recruited, in
order to have 1416 evaluable patients (for more details,
see Additional file 1, pages 48–49).
Statistical analyses
The difference in the proportion of UTIs (primary out-
come) between the single-dose AP and the 3-day AP arm
will be compared with the non-inferiority margin using a
two-sided 95% confidence interval calculated according to
the continuity-corrected modification of Wilson’s score
method [16]. The primary analysis will be based on the
intention-to-treat (ITT) principle (i.e. all patients will be
analysed according to the treatment group they were allo-
cated to). We will also conduct a per-protocol (PP) ana-
lysis including patients without any major protocol
deviation and for which the endpoint data are available.
Patients who miss more than one oral dose of study medi-
cation or who did not receive the intravenous TMP/SMX
due to any reasons will be classified as non-adherent to
the study drug and will be excluded from the per-protocol
analysis. We expect a very low rate of non-adherence to
the treatment regimens in both groups due to the nature
of the intervention. Thus, we do not expect substantial
differences between the ITT and PP analyses. We will base
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our interpretation on the ITT analysis under close con-
sideration of the results from the PP analysis when
reporting and communicating the results (for more de-
tails, see Additional file 1, page 51). For the ITT ana-
lysis, missing values will be imputed via multiple
imputation using fully conditional specifications (FCS)
implemented by the MICE algorithm as described by
van Buuren and Groothuis-Oudshoorn [17]. As a sensi-
tivity analysis, the ITT analysis will be repeated using the
inverse probability of censoring weighting (IPCW) meth-
odology [16]. The difference in the UTI rate between the
treatment arms will be estimated and reported with a 95%
confidence interval separately for patients treated with
TURP and patients treated with GL. No other subgroups
are pre-specified. No interim analyses will be conducted.
Secondary analyses will be exploratory in nature and
aim to measure the ITT effect. All estimates will be pre-
sented with 95% confidence intervals. Secondary analyses
will be performed primarily as complete case analyses. For
the key secondary endpoint (a) and secondary endpoints
(r) and (s), additional (sensitivity) analyses will be per-
formed, as described for the primary endpoint. For all
other secondary endpoints, missing data will only be im-
puted or IPCW applied if the amount of missing values is
considerable (i.e. more than 5% of values missing in one
treatment group, more missing values than events in one
group). This means that the number of patients may vary
among analyses.
The key secondary outcome (a) (symptomatic UTI
(based on clinical diagnosis supported by measured bac-
teriuria of ≥105 cfu/ml) treated with antibiotics) will be
analysed as described for the primary endpoint. Results
(size and direction of the effect) will be compared infor-
mally to the primary endpoint.
Secondary outcomes (b)–(m) will be analysed with
generalised linear mixed models (GLMM) with binomial
error distribution, including the treatment arm as pre-
dictor and the study centre as random effect. Estimates
will be reported as odds ratios.
Secondary outcomes (n)–(p) will be treated as count
data and analysed with GLMM with Poisson error distri-
bution, including the treatment arm as predictor and the
study centre as random effect. Estimates will be reported
as relative effects.
Secondary outcomes (r)–(s) will be analysed by means
of linear mixed models (LMM), including the treatment
arm as predictor and the study centre as random effect.
Estimates will be reported as absolute effects.
Data management and confidentiality
The data for the endpoints will be extracted from the
hospital information system and entered into the eCRF
by trained study nurses. Data entered into the eCRF will
be validated for completeness and discrepancies
automatically by implemented rules in the eCRF. An
audit trail will maintain a record of initial entries and
any changes made. For each patient enrolled, an eCRF
must be completed. The principal investigator and
co-investigator at the study site will be responsible for
assuring that the data entered into the eCRF are complete
and accurate, and that the entry and updates are performed
in timely manner. A delegated person from the sponsor/
principle investigator (i.e. Kathrin Bausch) and a designated
study monitor from the Clinical Trial Unit (CTU) Basel
will conduct a site initiation visit at each study site to verify
the qualifications of the local investigators, inspect the site
facilities and inform the investigators of their responsibi-
lities and the procedures for ensuring adequate and correct
documentation and use of the EDC system. In addition,
the study monitor from the CTU Basel will conduct two
routine monitoring visits per site—the first after inclusion
of one or two participants, the second after inclusion of the
last participant—as well as a site closure visit at the end of
the study to resolve any remaining queries.
Source data must be available at the study site to docu-
ment the existence of the study participants. Source data
must include the original documents related to the study,
as well as the medical treatment and medical history of
the participant. The study eCRF will be locked after all
data were entered or transferred. The complete dataset
will be exported and sent to the sponsor/principle investi-
gator via a secured protocol and according to standard
operation procedures (SOPs) of the CTU Basel. All study
data will be archived for a minimum of 10 years after
study termination or premature termination of the trial.
The study documentation and the source data will be
accessible to auditors/inspectors (e.g. audits from compe-
tent authorities) and questions will be answered during in-
spections. All involved parties must keep the patient data
strictly confidential.
Discussion
Antimicrobial resistance is particularly prevalent among the
main pathogens of the urogenital tract [18, 19]. Isolates
from urological patients show high antimicrobial resistance
rates. This has been explained by the frequent and ex-
tended use of antimicrobial agents partly for AP in standard
urological procedures [20]. Resistance rates have been in-
creasing in parallel with the use of antimicrobials [21].
Thus, guidelines should ensure that AP is reduced to a
minimum without increasing the postoperative complica-
tions for individual patients. Recently, EAU guidelines were
adapted in recommending no more explicit agents but sug-
gesting consideration of local pathogen prevalence and pre-
operative urine culture in order to reduce the use of
antimicrobials [22]. In 2017, 75.6% and 79.0% of Escherichia
coli were susceptible to TMP/SMX and fluoroquinolones
in north-western Switzerland [23]. Fluoroquinolones have a
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high propensity for collateral damage (i.e. ecological, AEs)
and therefore should be reserved for severe infections other
than AP or uncomplicated UTIs. In UTI treatment, their
use should be limited to patients who are allergic or resist-
ant to TMP/SMX [20].
Only a randomised controlled trial would be able to pro-
vide reliable evidence to guide decision-making on whether
single-dose AP is non-inferior compared to 3-day AP in
this setting. Non-randomised observational methods would
carry a high risk of bias and would not allow one to draw
causal inferences about the comparative merits of both
treatment strategies. Therefore, in this multicentre RCT, we
will investigate, in patients undergoing either TURP or GL
for obstructive voiding disorders, the non-inferiority of
single-dose AP with cotrimoxazole against 3-day AP with
cotrimoxazole in terms of the proportion of UTIs within
30 days which require antimicrobial treatment. The goal
would ultimately be to reduce AP without increasing the
rate of symptomatic UTIs treated with antibiotics. We
chose to extract the vast majority of endpoints (e.g. UTI,
urosepsis, prostatitis) from routinely collected data without
interfering much with the clinical routine to follow a prag-
matic approach which would have a high external validity.
A non-inferiority margin was chosen to preserve at least
70% of the original effect. In other words, when 100
patients undergoing TURP or GL would receive no treat-
ment, 24 (i.e. 23.68%) would have a symptomatic UTI and
76 patients not. If all of these 100 were treated with 3-day
AP, 9 (i.e. 9%) would still have a symptomatic UTI and 91
not. If all of these 100 were treated with a single AP (which
still has 70% of the effect), approximately 13 patients would
have a symptomatic UTI and 87 not. We would consider it
acceptable when approximately four more of 100 patients
(13 patients instead of 9) would have a UTI when bearing
in mind that these four UTIs can be treated relatively
straightforward with antibiotics and that simultaneously the
use of AP can be strongly decreased in all 100 treated pa-
tients. This may reduce individual adverse events and
development of resistant pathogens. Furthermore, lesser
antibiotic resistance has important beneficial consequences
for public health in general.
Trial status
The recruitment of patients (protocol version 1.1 11.9.2018,
supplement 1) has started after the submission of the study
protocol to Trials. At the time point of conducting revi-
sions (14–22 January 2019) we have so far enrolled 26
patients. We plan to enrol all patients from 1 November
2018 until 31 March 2022.
Additional files
Additional file 1: Clinical study protocol. (DOCX 638 kb)
Additional file 2: World Health Organization Trial Registration Data Set.
(DOCX 23 kb)
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